Company Profile
Erasca Stock Price, News & Analysis
Company overview
Business overview
Erasca is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Erasca is followed within the biotech universe for its exposure to catalyst-driven execution.
Business Model Characteristics
Erasca follows a catalyst-driven model where the market watches how the company turns development work into repeatable value creation.
Position Within the Biotechnology Landscape
Compared with more mature healthcare peers, Erasca sits closer to the development side of the biotechnology landscape, where timing around data and approvals matters most.
Why the stock is moving
ERAS is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Erasca’s next catalysts are its KRAS-pathway oncology programs and any combination-data update that shows the company can still build a credible precision-oncology story. The market will care about whether the pipeline continues to look more differentiated than crowded peers.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
- 02
- 03
Erasca to Present at Upcoming Conferences in February
Source: Erasca
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.